5 results
This study will evaluate the antitumor activity of RAD001 versus placebo in patients with angiomyolipoma associated with either TSC or LAM.
This study will evaluate the antitumor activity of RAD001 versus placebo in patients with subependymal giant cell astrocytomas (SEGA) associated with Tuberous Sclerosis Complex (TSC).
• To estimate the difference in the efficacy and safety of RAD001 10 mg p.o. daily dose in combination with bevacizumab 10 mg/kg administered intravenously every two weeks for first-line treatment of patients with metastatic carcinoma of the kidney…
Primary ObjectiveTo evaluate the efficacy and safety/tolerability of UK-432,097 DPI in adults with moderate to severe COPD (GOLD stage II/III).
To demonstrate that Nanocort is safe and effectively reduces the inflammatory signs and symptoms of active GO.